Kidney Payment Reform Still Depends on Referral and Intake Operations
Editorial revision: . Original publication and source dates are retained.
The Kidney Care Choices Model has shown quality gains alongside spending pressure. For kidney-care leaders, the next task is to connect payment incentives to reliable referral, education, intake, modality choice, and handoffs—and measure how those operations affect both care and cost.
Return to insightsKidney care entities, nephrology groups, dialysis networks, care-management platforms, payers, and healthcare operators / 2026-07-19
The strategic question
Which referral, intake, education, or care-coordination failure prevents a kidney payment model from becoming a better patient pathway?
Model findings and changes are attributed to CMS. Operating recommendations are independent analysis and do not claim clinical or financial outcomes for a specific organization.
Executive thesis
Reconcile quality improvement with the cost of delivery.
Kidney value-based care requires a reliable patient pathway and a sustainable payment model. CMS reports meaningful quality gains in home dialysis, optimal starts, and transplant-related measures alongside net Medicare losses that prompted financial-method changes and an extension through 2027. Leaders should manage these results together: identify patients earlier, resolve referral and intake barriers, support modality choice, and trace quality changes to their utilization and cost drivers.
Public facts
CMS says the Kidney Care Choices Model runs through 2027 and is intended to delay dialysis, support transplantation, reduce cost, and improve coordinated care for late-stage CKD and ESRD.
CMS reports that the model's second performance year improved home-dialysis use, optimal starts, and certain transplant measures while producing a statistically significant net Medicare loss for 2023.
CMS implemented 2026 financial and participation changes intended to improve sustainability, including benchmark discounts and changes to capitation and model options.
My assessment
I read the mixed result as a warning against underwriting a kidney-care business from a quality metric alone. A clinically valuable change can require additional coordination, preparation or treatment expenditure before any offset appears. The investment case must identify the costs retained by each organization, the payments tied to the model and the time horizon over which the proposed benefit could emerge.
Patient identification and referral timing are core levers. Late engagement reduces the opportunity for education, access placement, home readiness, transplant evaluation, and planned starts.
The intake system must expose clinical, payer, documentation, social, and capacity barriers in one work queue rather than distributing them across teams.
I would allocate the next increment of capacity to the binding pathway constraint: identification, clinical review, education, access preparation, receiving capacity or follow-through. More referrals are useful only when that constraint can absorb them. Compare cohorts by readiness and access barriers, while preserving clinically appropriate choice; a favorable average produced by selecting easier patients does not establish a scalable population-health service.
Operating model
Fund the binding constraint in the care pathway.
Assign responsibility at each handoff, then review pathway completion alongside quality and net spending.
Operating framework
- 01
Identify eligible patients early enough for education, nephrology engagement, and planned modality choice.
- 02
Map referral source, clinical readiness, payer status, documentation, scheduling, acceptance, and first treatment as one conversion path.
- 03
Give the patient a supported choice across delayed progression, home modalities, in-center care, transplant, and conservative care where appropriate.
- 04
Create shared work queues and escalation across nephrology, dialysis, transplant, primary care, and care management.
- 05
Measure quality and net spending with the operating drivers visible underneath them.
Metrics that matter
- 01
Time from identification to nephrology engagement
- 02
Planned and optimal dialysis starts
- 03
Home-modality education and activation
- 04
Referral acceptance and intake cycle time
- 05
Total cost and avoidable utilization by patient cohort
Buyer implications
Kidney operators should connect referral operations to quality and total-cost outcomes.
Payers should diligence the patient-identification, intake, education, modality, and exception workflow underneath reported results.
Technology partners should prove earlier action and completed handoffs, not merely risk identification.
Management priorities
Build the patient journey from first risk signal through longitudinal kidney care.
Instrument referral age, missing requirements, capacity, payer friction, and next owner.
Pair every quality metric with its utilization and cost drivers.
Use one high-friction corridor to prove the operating model before network expansion.
Red flags
Patients are identified after the window for education and planned choice has narrowed.
Referral dashboards do not expose missing documents, payer friction, or accountable owners.
Quality gains are reported without the operating and spending drivers needed to sustain them.
CEO and CFO questions
Where does the patient first become visible and who acts?
Which intake barriers delay an optimal start or modality choice?
How are nephrology, dialysis, transplant, and primary care handoffs governed?
Which quality improvement also changes net spending?
Before expanding, identify where the patient pathway breaks and fund the capacity to repair it. Require evidence that the revised pathway can sustain both care quality and its economics.
Map the kidney care pathwayDiscuss the strategic decision